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Profiling of individuals based on inborn, acquired, and assigned characteristics is
central for decision making in health care. In the era of omics and big smart data,
it becomes urgent to differentiate between different data governance affordances for
different profiling activities. Typically, diagnostic profiling is in the focus of researchers
and physicians, and other types are regarded as undesired side-effects; for example,
in the connection of health care insurance risk calculations. Profiling in a legal sense is
addressed, for example, by the EU data protection law. It is defined in the General Data
Protection Regulation as automated decision making. This term does not correspond
fully with profiling in biomedical research and healthcare, and the impact on privacy has
hardly ever been examined. But profiling is also an issue concerning the fundamental right
of non-discrimination, whenever profiles are used in a way that has a discriminatory effect
on individuals. Here, we will focus on genetic profiling, define related notions as legal and
subject-matter definitions frequently differ, and discuss the ethical and legal challenges.
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INTRODUCTION
In healthcare, potentials of big data receive more and more attention as the volume, variety, and
velocity of healthcare data is increasing steadily. Big companies, for example Google, Apple and
IBM are investing huge resources in this area in order to exploit their data assets. As data have an
intrinsic value, for example, as resource of gaining knowledge about human needs and preferences,
buying and selling them or using them for various purposes is tempting. Customizing product
offers and pricing based on our habits, needs, and characteristics usually increases profits in various
different areas, but might entail detrimental effects for the customer and unacceptable implications,
such as ethnical and gender discrimination, for the society as a whole. This danger does not
primarily stem from the central risk data protection law is addressing: the risk of unwarranted
disclosure of person-related data. It is rather the risk of creating general profiles, which are later
used in decision making, and might lead to unfair and discriminatory treatment. For such profile
creation, re-identification is not needed, i.e., in most cases, anonymized and aggregated data are
sufficient. An overall picture is given in Figure 1. Therefore, privacy preserving techniques are
rather toothless to mitigate these risks—one central purpose in generating anonymized data is to
allow inference of new patterns. In this paper, we deal with the question of how this kind of risks
associated with (genetic) profiles can be mitigated while harnessing their advantages for health
research and healthcare.
“By definition, big data in healthcare refers to electronic health data sets so large and complex
that they are difficult (or impossible) to manage with traditional software and/or hardware...”
(Rubin and Desser, 2008). One the one hand, many promises related to these large and complex
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FIGURE 1 | Two different domains of data processing are depicted. Processes on the left for generating secondary use data out of different sources (only three
general ones are given here) are related to data protection regulations. Processes on the right for inferring profiles are related to anti-discrimination regulations.
data still need to be realized; on the other hand, there are
fears regarding the increased misuse of those data. Both aspects
are consequences of the complexity that renders it impossible
to assess upfront the realizable benefits and misuses. Hence,
discussing big data challenges has a high risk of projecting
prejudices and it is important to reduce this risk by presenting
and exploring the relevant notions and legal frameworks.
Profiling in general is “as old as life” (Gutwirth and
Hildebrandt, 2010); it is the deduction of information based on
some characteristics of an individual or a group of individuals,
which are either known beforehand or also deduced. Generally,
profiling may be based on different grounds: human experience,
cultural stereotypes or statistical correlations. The result is always
a certain conclusion with respect to an individual based on the
assumption that the individual can be classified as belonging
to a certain group of individuals, who are assumed to exhibit
the same characteristics with a certain probability (European
Commission, 2018a). The possibilities introduced by big data
and methods such as data mining and deep learning allows new
levels of insights that shape our view of the present and the
future. Thus, the impact of profiling on society has been enlarged
in the era of big data and data mining methods. There are
many different contexts for profiling, e.g., information science,
healthcare settings, forensic science, marketing, etc. Big data
increases the usage possibilities of profiling for detecting new
patterns and automated decision making (Hildebrandt, 2008).
Profiling in healthcare is highly related to personalized
medicine, allowing better tailored decisions instead of those
based on average characteristics. Potential applications are:
biomarker-guided diagnosis decision and therapy selection,
prognostication, resistance detection, disease monitoring, risk
assessment, recurrence detection, and early detection (Wjst,
2010). Main challenges of profiling based on big data stem
from the deduction of knowledge leading to certain decisions
that are sensitive in an ethical and legal sense: it can lead to
non-transparent decision making and even unfair treatment and
discrimination of individuals. “Profiling can perpetuate existing
stereotypes and social segregation. It can also lock a person into a
specific category and restrict them to their suggested preferences.
This can undermine their freedom to choose, for example,
certain products or services such as books, music or newsfeeds.
It can lead to inaccurate predictions, denial of services and
goods, and unjustified discrimination in some cases” (European
Commission, 2018a).
It is well-known that many cultural assumptions are
statistically invalid and rather based on ideology and therefore
discriminating. Discrimination, however, can also occur, when
conclusions are based on valid correlations. This is the case,
if such correlations are in conflict with basic ethical decisions
of our society. Inequality based on gender for example is
considered unethical or even unlawful, even though there might
be a statistical difference in certain areas. Algorithms applied
to big data sources such as data mining techniques aggravate
the problems of profiling because new forms of knowledge
deduction become possible that allow faster and automated
ways of decision making with a lack of transparency, increasing
the risk of unwarranted disclosure, and unfair use of sensitive
information. One example of an unfair discrimination is the
decision to charge citizens having an increased risk of developing
diabetes due to their genetic disposition with a higher insurance
rate. For example, in the US, the Affordable Care Act of 2010
(ACA) does not prevent insurers from charging more for such
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expected conditions (Saloner and Daniels, 2011). This question
cannot be answered by statistical evidences only but must also
refer to ethical values and legal frameworks. Transparency in this
case means that such discriminatory practices and the methods
behind them should be disclosed to the public.
One way to consolidate such questions of discrimination and
transparency of profiling is to look into the decision-making
process. Rational decisions are a result of opinions (including
ethical values), experiences and empirical evidences. They are
cognitive processes of identifying and choosing a belief or a
course of action among several alternatives. By shifting toward
empirical facts and analyses, it becomes urgent to reconsider
the way the other components of decisions should be involved.
Statistical results seem to show an inherent credibility and
correctness due to the mathematical methods by which they
are developed. People tend to accept profiles and decisions
based on such results without seeking explanation or reasons
for the conclusions based on them. Providing a reasoning
for certain decisions beyond “facts” (which are themselves a
construction), however, is a basic requirement for preventing
unfair discrimination and allowing actionable transparency. It
is therefore necessary to balance data-driven results with norms
and thus keep control of their use in decision making. To
this end, we suggest new approaches for addressing the threats
of genetic profiling and also show the shortcomings of the
current European legal framework, mainly GDPR (General Data
Protection Regulation).
WHAT IS GENETIC PROFILING?
The term genetic profile is generally used to denote genetic
signatures or information as a combination of genetic
characteristics related to a human being. It is important
to emphasize that profiling is the process by which such a
combination of characteristics is associated with target attributes
used for decision making, e.g., concerning the risk of developing
a certain disease. The notion profiling can be summarized by
following two descriptions (European Commission, 2018a):
“... a procedure which may involve a series of statistical
deductions. It is often used to make predictions about people,
using data sources to infer something about an individual, based
on the qualities of others who appear statistically similar”
“... a means gathering information about an individual (or
group of individuals) and analyzing their characteristics or
behavior patterns in order to place them into a certain category
or group, and/or make predictions or assessment about, for
example, their ability to perform a task, interests, likely behavior.”
In health care, physicians use profiling as a part of their
professional duties. Another term that can be used is “risk
stratification,” i.e., using certain patient characteristics for
classifying different types of disease forming (Braithwaite et al.,
2016). Naturally, group-related characteristics often lead to the
risk of discrimination as soon as decisions with a direct impact
on the respective individuals are taken.
Genetic profiling is used in healthcare and biomedical
research for associating genetic characteristics with increased
or decreased likelihood of developing and overcoming certain
diseases. Rarely, diseases are monogenic, i.e., the diseases are
attributable to genetic variants at one locus with large effects on
disease status. Cystic fibrosis is an example of such a monogenic
disease. In the majority of cases, genetic disorders are polygenic,
meaning they are likely associated with the effects of multiple
genes in combination with lifestyles and environmental factors.
While there are many forms of DNA-related markers that are
relevant for certain phenotypes and identification of individuals,
generally only a tiny fraction of DNA is relevant for health care
and research, e.g., Genes, SNPs, Short Tandem Repeats (STR),
and whole genome sequences. These markers are directly related
to the DNA without any translation step in-between (in contrast
to, for example, RNA variants), which allows to focus on stable
characteristics at the molecular level. STRs are highly relevant,
because they are frequently used for genetic fingerprinting of
individuals (Sariyar et al., 2017).
With big data and related algorithms, especially stemming
from the domain of artificial intelligence (AI), genetic profiling
can and in some cases must be achieved by automated
decision making. Using methods like deep neural network are
additionally related with a black-box character, making it difficult
to achieve transparency regarding the mechanism for risk
prediction.We will discuss implications of these difficulties in the
next section.
For making the discussion of potentials and problems
of genetic profiling for individual as well as social profiling
more concrete, we will use diabetes mellitus as a disease
for which diagnosis and treatment can be tailored with
the help of genetic profiles. “Diabetes mellitus is a chronic
disease of major global health concern due to its increasing
prevalence in both developing and developed countries,
with a projection increase of 214% from the year 2000
to 2030” (Leung, 2016).
Use Case for Individual Genetic Profiling
for Diabetes Mellitus
In contrast to single-gene profiles for Mendelian disorders with
relatively certain prediction of developing a disease, genetic
profiling for diabetes mellitus type 2 (DMT2) only allow to
generate disease risk information (Haga, 2009). Among the
best studied causes are two closely linked single nucleotide
polymorphisms (SNPs) in the transcription factor 7-like 2
(TCF7L2) gene (O’Rahilly et al., 2005). Over 20 studies have
corroborated the association between these two SNPs in TCF7L2
and increased DMT2 risk. Several questions arise here, e.g.:
• How and when should predispositional screening for disease
prediction be used?
• To whom and how should the risk information
be communicated?
Use Case for Social Genetic Profiling for
Diabetes Mellitus
Here, social profiling does not refer to the construction of user’s
profile using social data, but to the process of attributing genetic
characteristics leading to phenotypes otherwise not directly
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attributable to a social group (Leung, 2016). With respect to
diabetes mellitus, the aboriginal population of Canada (including
the First Nations, Inuit and Metis) represents a frequently
investigated example. Among the Aboriginal population of
Canada, diabetes mellitus contributes significantly to their higher
morbidity when compared to the non-Aboriginal Canadians.
One explanation is the thrifty gene theory proposed by Neel
(1962): Aboriginal people had maintained a hunter-gatherer
lifestyle with no guarantee of the constant food supply, and
hence via evolution they acquire a thrifty gene to conserve energy
through periods of starvation and environmental hardships. In
view of this, Hegele et al. identified a gene mutation (G319S) in
the hepatic nuclear factor-1 alpha which translates to decreased
insulin sensitivity (Hegele et al., 1999, 2003). Overall, the crude
prevalence for diabetes ranges from 2.7 to 19%, which is
3–5 times higher than non-Aboriginal cohorts (Oster et al.,
2012). In order to reduce this high prevalence, the Federal
Government of Canada had launched the Aboriginal Diabetes
Initiative (ADI) in 1999 as part of the bigger Canadian Diabetes
Strategy to provide a better framework for surveillance, public
education, and community-based management of diabetes.
Following questions arise:
• How to prevent that this public knowledge is used for the
purpose of discrimination?
• Generally speaking, should it be allowed to have
racial screening?
LEGAL APPROACHES AND GAPS FOR
ADDRESSING GENETIC PROFILING
Data Protection Law
Profiling is a well-known concept in data protection law closely
linked to the application of statistical means and algorithms and
has already been addressed in the EU Data Protection Directive
of 1998. But the abundance of available information in the world
wide web and other sources together with an ever-increasing
knowledge of how to use them has been shedding new light on
it in the past years. EU Data protection law, however, has not
been able to keep pace with this shift. The same seems to be
true for other jurisdictions. The GDPR sticks to the concept of
controlling the ways personal data is processed, mainly by the
requirement of consent, if no other legal allowance is provided.
In the era of big data, insisting on the concept of personal data
that is protected and distinguished from anonymous data, which
is free to be used, is not appropriate to protect citizens against the
rule of algorithms and the wrong use of their results.
It is Art. 22 of the GDPR that addresses profiling by
prohibiting decisions “solely based on automated decisions,” not
covering other decision-making contexts using profiles. “As soon
as a human being reviews and takes account of other factors
in making the final decision, that decision would not be based
solely on automated processing” (European Commission, 2018a).
For these non-automated decisions, the creation and usage of
profiles remains untouched by Art. 22. In addition to that, the
application of data protection law is limited to the processing
of personal data. However, the use of personal data is often not
needed for profiling; anonymized data are often good enough to
create profiles.
As a result, the GDPR provides only limited means to prevent
undesired usage of profiles as well as the creation of profiles
through the use of non-personal, i.e., anonymous, data. At
least, the principle of transparency could support individuals
in questioning decisions based on profiles. The principle of
transparency, as it is mentioned in Art. 5, is one of the basic
rules in the GDPR. Under Articles 15 (Rubin and Desser,
2008) h, and 14 (Gutwirth and Hildebrandt, 2010) g, data
controllers must provide “meaningful information about the
logic involved, as well as the significance and the envisaged
consequences of such processing” to the data subject. But
neither of these provisions seems to contain the right to get
an explanation for a particular decision that has been made.
The only suggestion of such a right appears in Recital 71
of the GDPR, which says that appropriate safeguards should
include the ability of data subjects “to obtain an explanation
of the decision reached after such assessment” in cases of fully
automated decisions. Other forms of decisions are again not
addressed. The principle of transparency under the GDPR has
only a limited scope as the Art. 29 WP has described: “...the
controller must always be able to demonstrate that personal
data are processed in a transparent manner in relation to the
data subject. Connected to this, the accountability principle
requires transparency of processing operations in order that
data controllers are able to demonstrate compliance with their
obligations under the GDPR” (European Commission, 2018b).
There is no general requirement of letting individuals know,
what presumptions have led to a certain decision, e.g., having
full transparency how insurance rates are calculated seems to
be no right under the GDPR. In addition, there are a number
of legitimate reasons to hide a decision-making process, for
example intellectual property rights regarding methods and
algorithms used.
In view of this, concerns of citizens that their characteristics,
i.e., belonging to an ethnic group with an assumed genetic risk,
might be used without letting them know how and to what
extent, seems to be justified. The protection against profiling
is too weak and limited in scope to be effective in controlling
whether data are being misused. Even though, the creation
of a personal genetic profile based on personal data of the
concerned individual in an automated way might require the
consent of this individual according to Art. 22 GDPR, the
creation of genetic group profiles is not covered by the GDPR.
Such group profiles might be a factor in various decision-
making processes, without letting the customers know. It then
depends on the effectiveness of keeping one’s own genetic
characteristics secret whether they influence insurance rates.
In many cases, such as ethnic or family membership, this
is unrealistic. In addition, there is even a general obligation
for customers to reveal any known health impairments while
seeking insurance coverage. This is to a certain extent justified,
since otherwise a patient would be empowered to conclude
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for example a life insurance contract knowing that he/she is
going to die soon. The question is, whether or when a genetic
profile revealing certain risks must be considered detrimental to
the health status.
Anti-discrimination Law
Many jurisdictions contain a basic provision for prohibiting
discrimination, as it is laid down in various human rights
catalogs, e.g., Article 14 of the European Convention on Human
Rights. It is a basic principle of a democratic and open society
that people should exclusively be judged and treated according
to their free behavior—and not by inherited or otherwise
unchangeable attributes such as gender or race or by their
religious or political convictions. Article 9 of the GDPR reflects
the particular discriminatory potential of such data by providing
an enhanced protection of special categories of personal data,
including health data and genetic data. But here again, the scope
of the protection in the GDPR is very limited, as the GDPR does
not address the discrimination on the basis of such data as such.
The fundamental right to non-discrimination does not
explicitly comprise genetic information. Gender, race, and ethnic
origin are the central characteristics addressed by discrimination
laws. By using genetic information, these visible features can
often be deduced quite well. Hence, genetic data are an example
of proxy-data that can be used instead of visible phenotypes
without directly exhibiting the discriminatory purpose, as
they are frequently only available after sequencing within an
unsuspicious scientific context.
Since the discriminatory potential of genetic profiles,
especially in the field of insurance contracts and employments,
is quite obvious, there are attempts to restrict the use of such
profiles across jurisdictions. In 2008, the Genetic Information
Nondiscrimination Act (GINA) was adopted in the USA to
prohibit discrimination by health insurers or employers. Health
insurers (group, individual, and Medicare issuers) are prohibited
from adjusting premiums or contribution amounts, requesting
or requiring an individual or a family member of an individual
to undergo a genetic test, obtaining and using genetic test
results in making a determination regarding payment, or
requesting, requiring, or purchasing genetic information for
underwriting purposes. The statute does not cover schools,
mortgage lending, or housing. And it excludes other forms
of insurance like life insurance, long-term care, and disability
insurance. Therefore, the American Medical Association has
pointed to the shortcomings at an early stage (Prince and Roche,
2014). In Germany, the “Gendiagnostikgesetz” adopted in 2009,
contains similar clauses including life insurance. In the UK,
The Concordat and Moratorium on Genetics and Insurance
2014 (Genetics and Insurance ABI, 2018) regulates how genetic
information are to be used for calculating risks. These Anti-
discrimination acts or declarations, however, are as limited in
scope as the GDPR is. They do not cover the use of genetic
profiles in all cases, but only to the extent explicitly regulated.
In addition, antidiscrimination law has often been considered
toothless, since it is only applied when it can be proved that a
decision has been based on discriminatory presumptions. This
proof is always difficult. It might be even more difficult if the
decision-making procedure is not transparent.
Implications of the Use Case for Individual
Profiling
One central issue for individual profiling is related to the reason
of generating a profile and secondary use scenarios for profiles.
From an ethical point of view, informed consent of the individual
or its guardian is crucial. It should be known for what primary
purpose and with which benefits as well as disadvantages such
a profiling is associated. In the research setting, the purpose
of gaining insights into average responses is more and more
replaced by the goals of individualized medicine. This renders
genetic profiles more important than they were before, which is
one reason why the GDPR has explicitly included genetic data
into the definition of sensitive data. While research as such poses
rather few risks of discrimination, translating the results into
the health care increases the likelihood of being discriminated,
mainly because risk probabilities have to be translated into binary
decisions with economic impacts. Hence, if diabetes mellitus is
diagnosed with a certain probability, it depends on the context
and the decision-making procedures whether and how this
probability is sufficient for causing certain actions.
A health care provider can in most cases only relate to
the medical implications. However, other stakeholders such as
employers or insurance companies might use genetic profiles
and associated risks for other forms of decisions. It depends
on the legal context whether an individual have to disclose his
genetic profile and the associated risk to these other stakeholders
or if he can keep this information secret. Even if the legislator
prohibits the usage of certain profiles in health care settings,
it will rather be difficult to prevent discriminations if there are
scientifically known or knowable differences in risks for different
profiles. With respect to life insurance companies, there is often
a gray area. Legislation such as GINA do not cover them fully,
which means that there is no prohibition for requiring existing
profiles in order to compute overall survival probabilities. If
there are no such profiles, it would be rather unlikely that they
have to be provided because of the huge number of genetic
tests that could be done. This means that increased knowledge
about oneself increases the possibility of discrimination. Making
the individual aware of this fact and increasing his decision
competencies are goals that could accompanied by legal rules for
advisory committees and increased transparency requirements.
Implications of the Use Case for Social
Profiling
Due to the potential of racial discrimination, group profiling
based on genetic data is one of the most prominent form
of profiling in the context of health research. Knowing from
research that prevalence for diabetes is 3–5 times higher for the
Aboriginal population than for the non-Aboriginal population, it
is difficult to prevent discrimination on that basis. Prohibitions
can bring about a certain amount of certainty, but with the
potentials of big data and artificial intelligence, research and
data processing achieve a new level of knowledge generation. In
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view of this, genetic repositories as the ones of the Wellcome
trust restricted access to their data (Zerhouni and Nabel,
2008). Mostly, privacy concerns are given as reasons for these
restrictions. However, group profiling can still be done with
anonymized and aggregation data. Discrimination risks aremuch
harder to assess than privacy breaching risks, as there are many
routes for achieving results on groups. Here again, the legislator
should increase transparency requirements and it seems that this
is the best he can do, as it is infeasible to list and regulate all
applications that might be harmful.
DISCUSSION AND CONCLUSION
There has always been a debate whether or under what
circumstances research, which lead almost always to some sort of
profiles, might be harmful. As the diabetes use case shows, group
profiling within health research and healthcare has many positive
effects, e.g., better prevention, public education and community-
basedmanagement of diabetes. Hence, ethnical/genetic screening
can in principle be beneficial for the citizens’ well-being.
Furthermore, we assume that there is no evil scientific research
as such, but its results can of course always be used for malicious
purposes and thus raise ethical concerns. In some rare cases,
concrete research projects might pursue ethically questionable
goals or might be based on questionable methods. But those
seem to be rare. Research Ethics Committees or Review Boards
are in charge of this. Most societies have a well-established
system of research ethics, and there is an even older tradition in
medical ethics.
Research is as necessary for societies as personal freedom,
and research is as protected by fundamental rights as privacy
is. But citizens have to be protected against an uncontrollable
and unfair use of knowledge that has been derived from “their”
available data, even if this data is not identifying. Otherwise, we
risk ending up in a society where citizens are afraid of revealing
information about their life and health status due to the concern
that this information might lead to unfair treatment. This is
detrimental for research as well as for any democratic society.
But how could such a protection look like without leading to
an overcontrolled and restricted use of information preventing
free research and gaining insights beyond a highly regulated and
maybe overcontrolled institutional research? How to balance the
free flow of information for the sake of freedom and progress
with the legitimate interests of individuals not to be treated in the
basis of presumptions, they cannot even challenge due to their
complexity or due to protected IP?
The simple solution is to keep research and health care data
secret, e.g., by storing patient-related data at safe storage places,
and preventing their use for any other purpose than for health
care and research. This is exactly the approach of the GDPR:
personal data collected for specific purposes such as health care or
a certain research project must not be used for any other purpose.
But we all know the shortcomings of this approach: non-personal
data are not covered, and even genomic data are frequently
considered anonymous data under various jurisdictions despite
the high risk of re-identification once those data have left any
protected privacy preserving system. On the other hand, the
restrictions for research are often quite harsh in relation to the
success of keeping crucial data secret. For example, as soon as the
patient receives relevant health information derived from genetic
analysis, he/she might even be obliged to reveal those risks while
concluding an insurance contract, while usage of the same data
in another research project might be prohibited.
Big data and related methods foster new opportunities in
gaining new knowledge in secondary data use contexts that
even might not be considered scientific, which means that
the boundary between science and application blurs. It is
difficult and often impossible to expand principles and rules
for clinical research to all of these secondary use contexts;
hence, the discrimination potentials are growing in an ever-
increasing rate. This development makes the core question
more acute: How to mitigate risks associated with (genetic)
profiles while harnessing their advantages for health research
and healthcare?
If society does not want to slow down developments in
data science, solutions cannot rely on prohibitions of all kind
applications, but has to focus on increased transparency as well as
on ethical debates regarding good and bad purposes of profiling
independently of economic impacts.
For answering the question of how to prevent the use of
personal genetic profiles derived from personal health records or
research data bases for discrimination, it has first to be decided
where, by whom, by which security technique, under which
format and under which rules such profiles are stored. In order to
guarantee as much freedom as possible, disclosing of information
should mainly dependent on the free will of the data subject.
However, health insurances, life insurances, etc., want to be able
to customize their offers according to the information they can
receive from their customers. If such information is available, it
is difficult to prevent its usage. Most important, however, is the
fact, that in many cases, such as ethnic or family membership,
it is unrealistic to hide certain genetic characteristics. As the
diabetes case clearly shows, it is not the personal genetic profile
of a certain individual that is harmful for an individual’s life
opportunities, but the mere fact that he/she obviously belongs
to a certain group. The “typical” genetic profile due to ethnic
origin is sufficient to trigger assumptions about the health status.
The same will become true for an increasing number of genetic
group profiles connected to obvious characteristics. In contrast to
other profiles based, for example, on the outer appearance, such
genetic profiles are related to a broad range of aspects, which are
not immediately visible.
As AI algorithms can lead to socially unintended
discrimination, a public debate on the transparency of the
decision-making process and results of machine learning
algorithms is necessary. It should be clear: Algorithms do not
rule us but provide the result we need for decisions. The public
debate has to determine how transparency with respect to the
algorithms, underlying assumptions, and their results can be
achieved. What we need, is a general right to get to know and
assess the presumptions behind decisions affecting individuals.
This is highly relevant, as it is possible to hide characteristics
such as race or genetic disposition behind less suspect items that
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are highly correlated with them. The latter is all the more true
regarding social profiling, which does not need personal data and
can therefore undermine privacy of individuals that have kept
their profiles secret.
In conclusion, decisions concerning individuals should always
be challengeable, especially when sensitive genetic information
is involved. Regulations regarding genetic profiles cannot cover
all possible uses and misuses, which means that the legal
gap cannot be closed only by more detailed prohibitions. In
addition to that, mechanisms of oversight should be established,
allowing standardized and transparent procedures for deciding
whether the use of genetic profiles is based on unjustified or
discriminatory assumptions.
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